A comprehensive systematic review of the effectiveness of Akkermansia muciniphila, a member of the gut microbiome, for the management of obesity and associated metabolic disorders

Arch Physiol Biochem. 2023 Jun;129(3):741-751. doi: 10.1080/13813455.2021.1871760. Epub 2021 Jan 15.

Abstract

Aims and background: Obesity is recognised as a significant public health burden worldwide. Recently the cross-talk between gut microbiota and obesity has attracted much attention. To that end, Akkermansia muciniphila has been proposed as a promising microbe to manage obesity. In the present systematic review, we evaluated evidence on the effectiveness and mechanisms of action of Akkermansia muciniphila supplementation in the management of obesity.

Methods: Electronic databases of MEDLINE, PubMed, Scopus, Web of Science, and Google Scholar were searched thought March 2020 to identify relevant published articles, and eligible articles were systematically reviewed.

Results and conclusions: Fifteen studies were included in the present study. Findings from the present review, which included human and animal (rodent) models support the effectiveness of Akkermansia supplementation as a novel therapeutic approach for the management of obesity and metabolic complications associated with obesity. However, future clinical trials are warranted to verify these outcomes.

Keywords: A. muciniphila; Akkermansia muciniphila; gut microbiota; weight loss obesity.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Akkermansia*
  • Animals
  • Diet
  • Gastrointestinal Microbiome*
  • Humans
  • Metabolic Diseases* / microbiology
  • Metabolic Diseases* / therapy
  • Obesity* / microbiology
  • Obesity* / therapy
  • Probiotics* / therapeutic use

Supplementary concepts

  • Akkermansia muciniphila